BlogHeader.png

Case Study: Abeona Therapeutics

Abeona LogoAbeona Therapeutics, Inc. is a fully-integrated gene and cell therapy company at the forefront of the rapidly-advancing field of genetic medicine. Their late-stage candidate, EB-101, is an autologous, ex-vivo, gene-corrected cell therapy poised to enter a Phase 3 clinical trial for Recessive Dystrophic Epidermolysis Bullosa (RDEB).

Read this case study to learn how Alcami's extensive experience with small and large molecule development services, regulatory compliance, and specialty techniques helped ensure the quality, safety, and efficacy of raw materials used in Abeona's EB-101 manufacturing batches.

Download Case Study Here
Topics: Resource Center Regulatory Compliance Biologics Analytical Testing Analytical Development Orphan Drugs